As previous literature has indicated that the predictive value of TOMM40 ‘523’ in late-onset AD primarily applies to carriers of APOE ε3, analyses were conducted again within the dominant sub-group of APOE ε3/ε3 carriers (n = 205). This evidence concerns the gene APOE and Alzheimer disease.